Oral

[O2-4] SARS2-4

Mon. Nov 14, 2022 3:20 PM - 4:50 PM Room 4 (Conference Room 107)

Chair:Yukiko Muramoto(Kyoto University), Shintaro Shichinohe(Research Institute for Microbial Diseases)

+Add all to schedule

3:20 PM - 3:35 PM

[O2-4-7] In vivo imaging of the cellular pathophysiology in SARS-CoV-2-infected mouse lung

*Hiroshi Ueki^1,2, I-Hsuan Wang³, Wataru Kamitani⁴, Yoshihiro Kawoka^1,2,5 (1. University of Tokyo, 2. National Center for Global Health and Medicine, 3. Academia Sinica, Taiwan, 4. Gunma University, 5. University of Wisconsin-Madison)

3:35 PM - 3:50 PM

[O2-4-8] The SARS-CoV-2 Omicron BA.1 spike G446S potentiates antiviral T cell immunity

*Chihiro Motozono¹, Mako Toyoda¹, Toong Seng Tan¹, Hiroshi Hamana², Yoshihiko Goto¹, Takeshi Nakama¹, Yoshiki Aritsu³, Mizuki Kitamatsu³, Keiko Udaka⁴, Hiroyuki Kishi², Takamasa Ueno¹ (1. Kumamoto University, 2. Toyama University, 3. Kindai University, 4. Kochi University)

3:50 PM - 4:05 PM

[O2-4-9] Determinants of the magnitude and breadth of SARS-CoV-2 neutralization after breakthrough infection.

*Sho Miyamoto¹, Takeshi Arashiro², Akira Ueno¹, Takayuki Kanno¹, Shinji Saito¹, Harutaka Katano¹, Shun Iida¹, Akira Ainai¹, Seiya Ozono¹, Takuya Hemmi¹, Yuichiro Hirata¹, Saya Moriyama³, Ryutaro Kotaki³, Hitomi Kinoshita⁴, Souichi Yamada⁴, Shuetsu Fukushi⁴, Yoshimasa Takahashi³, Tadaki Suzuki¹ (1. Department of Pathology, National Institute of Infectious Diseases, 2. Center for Surveillance, Immunization, and Epidemiologic Research, National Institute of Infectious Diseases, 3. Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, 4. Department of Virology I, National Institute of Infectious Diseases)

4:05 PM - 4:20 PM

[O2-4-10] Development of live-attenuated SARS-CoV-2 vaccine platform based on temperature sensitive strains

*Akiho Yoshida^1,2, Shinya Okamura^1,2, Sayuri Komatsu^1,2, Shiro Takekawa², Koichi Yamanishi², Hirotaka Ebina^1,2 (1. Virus Vaccine group, BIKEN Innovative Vaccine Research Alliance Laboratories, Institute for Open and Transdisciplinary Research Initiatives, Osaka University, 2. The Research Foundation for Microbial Diseases of Osaka University)

4:20 PM - 4:35 PM

[O2-4-11] Single dose intranasal inoculation of SARS-CoV-2 spike protein with mucoadhesive polymer enhances the mucosal and systemic immunogenicity

*Tomoko Honda¹, Sakiko Toyama¹, Yusuke Matsumoto¹, Takahiro Sanada¹, Fumihiko Yasui¹, Takashi Miyazaki², Takashi Kamishita², Natsumi Kodake², Michinori Kohara¹ (1. Tokyo Metropolitan Institute of Medical Science, 2. Toko Yakuhin Kogyo Co. )

4:35 PM - 4:50 PM

[O2-4-12] An LC16m8Δ-vectored COVID-19 vaccine effectively elicits neutralizing antibodies and cellular immune responses in a mouse model

*Hiroaki Osawa¹, Akihiko Sakamoto¹, Hinata Hashimoto¹, Tetsushi Mizuno^1,2, Ryohei Ogawa³, Keigo Mitsuhashi¹, Saya Yamauchi¹, Kyohei Yamagata¹, Mitsuhiro Iyori^1,4, Hisatoshi Shida⁵, Shigeto Yoshida¹ (1. Kanazawa University School of Pharmacy, 2. Kanazawa University School of Medicine, 3. Toyama University Faculty of Science, Department of Medicine, 4. Faculty of Pharmacy, Musashino University, 5. Institute for Genetic Medicine, Hokkaido University)

Session information